Human papillomavirus type 18 E6 and E7 antibodies in human sera: increased anti-E7 prevalence in cervical cancer patients

Antibody-reactive regions on the human papillomavirus type 18 (HPV-18) E6 and E7 proteins were identified with rabbit polyclonal anti-fusion protein sera by screening of an fd phage expression library containing subgenomic HPV-18 DNA fragments and by testing of overlapping decapeptides representing the E6 and E7 open reading frames. Peptides comprising the delineated regions (designated E6/1 to E6/4 and E7/1) were synthesized and used in an enzyme-linked immunosorbent assay (ELISA) to detect anti-HPV-18 antibodies in human sera. A total of 232 human serum samples (identical numbers of cervical cancer patients and age-matched controls) collected in Tanzania were tested. Similar prevalences (between 0.8 and 4.3%) of antibodies recognizing the different E6 peptides were found in the sera from tumor patients and controls. With a synthetic 28-mer peptide (designated pepE701) comprising the E7/1 region, a significant difference was found: 10 of 116 tumor serum samples but 0 of 116 control serum samples showed a specific reaction (P less than 0.001). This observation confirms earlier results with HPV-16 E7 fusion proteins (I. Jochmus-Kudielka, A. Schneider, R. Braun, R. Kimmig, U. Koldovsky, K. E. Schneweis, K. Seedorf, and L. Gissmann, J. Natl. Cancer Inst. 81:1698-1704, 1989). A lower prevalence of anti-HPV-18 E7 antibodies was observed when 188 human serum samples collected in Germany from tumor patients and controls were tested (3 of 94 positive in the cancer group; 0 of 94 positive in the control group). The type specificity of anti-HPV-18 E7 antibodies was demonstrated when the HPV type found by Southern hybridization in the cervical cancer biopsies was compared with seroreactivity: 4 of 8 serum samples obtained from HPV-18 DNA-positive but 0 of 16 serum samples from HPV-18 DNA-negative tumor patients reacted in the HPV-18 E7 ELISA. In addition, HPV-18-positive sera failed to react in a peptide ELISA with the homologous HPV-16 E7 region (M. Müller, H. Gausepohl, G. de Martinoff, R. Frank, R. Brasseur, and L. Gissmann, J. Gen. Virol. 71:2709-2717, 1990) and vice versa.

[1]  O. Dapunt,et al.  Skin test for HPV type 16 proteins in cervical intraepithelial neoplasia , 1991, The Lancet.

[2]  P. Stern,et al.  Loss of MHC class‐I expression in cervical carcinomas , 1990, International journal of cancer.

[3]  I. Frazer,et al.  Identification of B-epitopes in the human papillomavirus 18 E7 open reading frame protein. , 1990, Journal of immunology.

[4]  R. Brasseur,et al.  Identification of seroreactive regions of the human papillomavirus type 16 protein E4, E6, E7 and L1. , 1990, The Journal of general virology.

[5]  D. Galloway,et al.  Evidence of prevalent genital-type human papillomavirus infections in adults and children. , 1990, The Journal of infectious diseases.

[6]  I. Frazer,et al.  Identification of B epitopes in human papillomavirus type 16 E7 open reading frame protein. , 1990, The Journal of general virology.

[7]  J. Dillner,et al.  Mapping of linear epitopes of human papillomavirus type 16: The L1 and L2 open reading frames , 1990, International journal of cancer.

[8]  H. Ikenberg.  Human Papillomavirus DNA in Invasive Genital Carcinomas , 1990 .

[9]  R. Kimmig,et al.  Antibodies against the human papillomavirus type 16 early proteins in human sera: correlation of anti-E7 reactivity with cervical cancer. , 1989, Journal of the National Cancer Institute.

[10]  S. Wilczynski,et al.  Human Papillomavirus Genotype as a Prognostic Indicator in Carcinoma of the Uterine Cervix , 1989, Obstetrics and gynecology.

[11]  H. Hausen,et al.  Papillomaviruses in anogenital cancer as a model to understand the role of viruses in human cancers , 1989 .

[12]  J. Dillner,et al.  A synthetic peptide defines a serologic IgA response to a human papillomavirus-encoded nuclear antigen expressed in virus-carrying cervical neoplasia. , 1989, Proceedings of the National Academy of Sciences of the United States of America.

[13]  L. Twiggs,et al.  Prognostic significance of the presence of human papillomavirus DNA in patients with invasive carcinoma of the cervix , 1989, Cancer.

[14]  G. P. Smith,et al.  Antibody-selectable filamentous fd phage vectors: affinity purification of target genes. , 1988, Gene.

[15]  W. J. Dower,et al.  High efficiency transformation of E. coli by high voltage electroporation , 1988, Nucleic Acids Res..

[16]  A. Schneider-Gädicke,et al.  Identification of the human papillomavirus type 18 E6 and E6 proteins in nuclear protein fractions from human cervical carcinoma cells grown in the nude mouse or in vitro. , 1988, Cancer research.

[17]  D. Galloway,et al.  Identification of immunoreactive antigens of human papillomavirus type 6b by using Escherichia coli-expressed fusion proteins , 1988, Journal of virology.

[18]  G. Temple,et al.  Possible prognostic significance of human papillomavirus type in cervical cancer. , 1988, Gynecologic oncology.

[19]  W. Conover,et al.  Locally most powerful tests for detecting treatment effects when only a subset of patients can be expected to "respond" to treatment. , 1988, Biometrics.

[20]  Ad Dayan,et al.  The Design and Analysis of Long-Term Animal Experiments , 1987 .

[21]  G. Temple,et al.  Oncogenic association of specific human papillomavirus types with cervical neoplasia. , 1987, Journal of the National Cancer Institute.

[22]  H. Shirasawa,et al.  Integration and transcription of human papillomavirus type 16 and 18 sequences in cell lines derived from cervical carcinomas. , 1987, The Journal of general virology.

[23]  T. Oltersdorf,et al.  Identification of early proteins of the human papilloma viruses type 16 (HPV 16) and type 18 (HPV 18) in cervical carcinoma cells. , 1987, The EMBO journal.

[24]  A. Schneider-Gädicke,et al.  Different human cervical carcinoma cell lines show similar transcription patterns of human papillomavirus type 18 early genes. , 1986, The EMBO journal.

[25]  N. Hacker,et al.  PROSPECTIVE EVALUATION OF RISK OF CERVICAL CANCER AFTER CYTOLOGICAL EVIDENCE OF HUMAN PAPILLOMAVIRUS INFECTION , 1986, The Lancet.

[26]  B. Beutler,et al.  Cachectin and tumour necrosis factor as two sides of the same biological coin , 1986, Nature.

[27]  G. P. Smith,et al.  Filamentous fusion phage: novel expression vectors that display cloned antigens on the virion surface. , 1985, Science.

[28]  R. Schlegel,et al.  Presence and expression of human papillomavirus sequences in human cervical carcinoma cell lines. , 1985, The American journal of pathology.

[29]  R. Meloen,et al.  Small peptides induce antibodies with a sequence and structural requirement for binding antigen comparable to antibodies raised against the native protein. , 1985, Proceedings of the National Academy of Sciences of the United States of America.

[30]  D. Melton,et al.  Efficient in vitro synthesis of biologically active RNA and RNA hybridization probes from plasmids containing a bacteriophage SP6 promoter. , 1984, Nucleic acids research.

[31]  H. M. Geysen,et al.  Use of peptide synthesis to probe viral antigens for epitopes to a resolution of a single amino acid. , 1984, Proceedings of the National Academy of Sciences of the United States of America.

[32]  H. Hausen,et al.  A new type of papillomavirus DNA, its presence in genital cancer biopsies and in cell lines derived from cervical cancer. , 1984, The EMBO journal.

[33]  D. Hanahan.  Studies on transformation of Escherichia coli with plasmids. , 1983, Journal of molecular biology.

[34]  G. P. Smith,et al.  A new filamentous phage cloning vector: fd-tet. , 1980, Gene.

[35]  C. Selve,et al.  Reactifs de couplage peptidique I (1) - l'hexafluorophosphate de benzotriazolyl N-oxytrisdimethylamino phosphonium (B.O.P.) , 1975 .

[36]  A safer substitute for benzidine in the detection of blood , 1974 .

[37]  W. Wood,et al.  Host specificity of DNA produced by Escherichia coli: bacterial mutations affecting the restriction and modification of DNA. , 1966, Journal of molecular biology.